These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19035904)

  • 1. Treatment of metastatic urothelial cancer: opportunities for drug discovery and development.
    Sonpavde G; Sternberg CN
    BJU Int; 2008 Nov; 102(9 Pt B):1354-60. PubMed ID: 19035904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel agents for muscle-invasive and advanced urothelial cancer.
    Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
    BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current optimal chemotherapy for advanced urothelial cancer.
    Sonpavde G; Galsky MD; Hutson TE
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):51-61. PubMed ID: 18095883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving role of chemotherapy in advanced urothelial cancer.
    Calabrò F; Sternberg CN
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.
    Abe T; Shinohara N; Harabayashi T; Sazawa A; Maruyama S; Suzuki S; Nonomura K
    Eur Urol; 2007 Oct; 52(4):1106-13. PubMed ID: 17367917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
    Kollmannsberger C; Bokemeyer C
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):167-72. PubMed ID: 18685416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
    Inoue T; Obara T; Saito M; Kumazawa T; Yuasa T; Matuura S; Tsuchiya N; Satoh S; Habuchi T
    Hinyokika Kiyo; 2007 Sep; 53(9):613-8. PubMed ID: 17933135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
    Milowsky MI; Stadler WM; Bajorin DF
    BJU Int; 2008 Nov; 102(9 Pt B):1339-44. PubMed ID: 19035902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents for advanced bladder cancer.
    Sonpavde G; Elfiky AA; Rosenberg JE
    Ther Adv Med Oncol; 2009 Jul; 1(1):37-50. PubMed ID: 21789112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant systemic therapy for urological malignancies.
    Sonpavde G; Sternberg CN
    BJU Int; 2010 Jul; 106(1):6-22. PubMed ID: 20553475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of systemic therapy for advanced pancreatic cancer.
    El-Rayes BF; Philip PA
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer.
    Calabrò F; Sternberg CN
    Eur Urol; 2009 Feb; 55(2):348-58. PubMed ID: 18977070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.
    Tsuchiya N; Inoue T; Narita S; Kumazawa T; Saito M; Obara T; Tsuruta H; Horikawa Y; Yuasa T; Satoh S; Habuchi T
    J Urol; 2008 Dec; 180(6):2389-95. PubMed ID: 18930278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic chemotherapy options for metastatic bladder cancer.
    Siefker-Radtke A
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):877-85. PubMed ID: 16761931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?
    Yafi FA; Kassouf W
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):747-52. PubMed ID: 19496711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy for urological cancer : usefulness and feasibility of current protocols].
    Hara I; Motoo Y
    Hinyokika Kiyo; 2011 Mar; 57(3):151-2. PubMed ID: 21586888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Urological cancer].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):193-8. PubMed ID: 19223735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Pu YS; Vogelzang NJ
    BJU Int; 2008 Apr; 101(7):795-803. PubMed ID: 18070193
    [No Abstract]   [Full Text] [Related]  

  • 20. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ-preserving therapy in carefully selected patients.
    Heidenreich A
    Eur Urol; 2008 Jul; 54(1):21-3. PubMed ID: 18262722
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.